Biomarin Pharmaceutical Inc (BMRN)

Fixed asset turnover

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Revenue (ttm) US$ in thousands 2,830,220 2,731,722 2,563,532 2,443,023 2,373,030 2,261,604 2,184,719 2,123,138 2,059,481 1,999,471 1,903,678 1,871,615 1,827,451 1,829,463 1,891,778 1,815,339 1,822,817 1,822,364 1,813,337 1,772,797
Property, plant and equipment US$ in thousands 1,043,040 1,045,410 1,052,900 1,060,420 1,066,130 1,067,160 1,067,280 1,068,140 1,073,370 1,051,820 1,049,460 1,039,540 1,035,460 1,024,790 1,026,580 1,022,470 1,032,470 1,015,060 1,010,920 1,009,970
Fixed asset turnover 2.71 2.61 2.43 2.30 2.23 2.12 2.05 1.99 1.92 1.90 1.81 1.80 1.76 1.79 1.84 1.78 1.77 1.80 1.79 1.76

December 31, 2024 calculation

Fixed asset turnover = Revenue (ttm) ÷ Property, plant and equipment
= $2,830,220K ÷ $1,043,040K
= 2.71

The fixed asset turnover ratio for Biomarin Pharmaceutical Inc has been gradually improving from 1.76 in March 2020 to 2.71 in December 2024. This indicates that the company has become more efficient in generating revenue from its fixed assets over the years. A higher fixed asset turnover ratio generally signifies better asset utilization and operational efficiency. Biomarin Pharmaceutical Inc's increasing fixed asset turnover ratio suggests that the company is effectively using its fixed assets to generate sales and is managing its assets efficiently. This trend is positive for the company as it demonstrates an improvement in asset efficiency and operational performance over the analyzed period.